You are here
Nestle turns to mums after 150 years of selling infant formula
AFTER spending more than a century selling baby formula, Nestle SA realised it has neglected another potential customer: mom.
The Swiss food giant is expanding its offering for expecting and lactating women to add products that it says will help reduce health risks related to motherhood. The business could generate US$500 million to US$1 billion in 10 years, according to Thierry Philardeau, head of Nestle's nutrition business. That's up from about US$80 million now.
"We want to be at the junction of food and pharma," Mr Philardeau said in an interview at the company's headquarters in Vevey.
Nestle's current offering ranges from supplements aimed at helping to prevent gestational diabetes, introduced last year, to fortified milk powder for mothers. A 2015 analysis of studies by Cochrane, which reviews medical evidence for decision-making in healthcare, found a potential benefit from use of the key ingredient, myo-inositol, for prevention of the condition. In the future, products under Nestle's Materna brand might include infused teas or supplements intended to ward off premature births.
Such products could broaden Nestle's reach to mothers who don't buy its infant formula, offering growth opportunities in a market that's vulnerable to the slowing pace of births in much of the world. Chief executive officer Mark Schneider is pushing to expand the company's fastest-growing businesses, which also include coffee and pet food, while scaling back sluggish areas like packaged meat and candy.
In baby food, Nestle is the market leader, with 20 per cent of the US$82 billion business, according to Euromonitor International. But competition is heating up among the Swiss company, Danone and Reckitt Benckiser Group Plc, which acquired Mead Johnson in 2017. New Zealand-based upstart A2 Milk Co has been gaining ground in the key Chinese market with a type of infant formula that's easier to digest, which has prompted the Swiss company to follow suit.
Malnutrition and obesity in pregnancy increase the risk of a long list of health issues for offspring, including diabetes and cardiovascular disease, according to the World Health Organization.
Convincing mothers of the benefits of supplements is the biggest challenge, Mr Philardeau said. Nestle is meeting with gynaecologists and pharmacies and is boosting its sales force.
While Nestle may be the first multinational baby-food maker with big plans to push into the segment, the niche is already occupied by smaller, often local competitors. In Asia, China Mengniu Dairy Co and Japan's Otsuka Pharmaceutical are among the makers of powdered milk formula for pregnant women, while Europe and America count scores of prenatal-vitamin brands.
Nestle bought one such vitamin maker, Garden of Life, in 2017 when it acquired parent company Atrium Innovations for US$2.3 billion. It's shifting into higher gear after that purchase, and could take advantage of Atrium's distribution network, according to Alain Oberhuber, an analyst at MainFirst Bank.
At Nestle, Mr Philardeau plans to focus on selling products aimed at preventing specific issues women face when pregnant or breastfeeding, such as gestational diabetes, premature births and breast pain. The company already sells some of the more common products for mothers, such as supplements featuring probiotics, folic acid or vitamin D.
Nestle's range for pregnant women and mothers is already available in Mexico, Canada and China. BLOOMBERG